Convalescent plasma does not reduce risk of intubation or death for COVID-19 hospitalized patients

convalescent plasma does not reduce risk of intubation or death for covid 19 hospitalized patients

Sumary of Convalescent plasma does not reduce risk of intubation or death for COVID-19 hospitalized patients:

  • However, the study also revealed that the antibody profile in the blood of people who have had the virus is extremely variable and this may modify the response to the treatment.
  • The Canadian-led international research team also found that patients receiving convalescent plasma experienced significantly more serious adverse events than those receiving standard care.
  • The clinical trial, called CONCOR-1, stopped enrolment early in January 2021 after its independent data safety monitoring committee recommended the study was unlikely to demonstrate a benefit of convalescent plasma even if more patients were enrolled.
  • A secondary discovery was that convalescent plasma had highly variable donor antibody content due to the highly variable immunological response to the virus.
  • Different antibody profiles in the convalescent plasma were observed to significantly impact whether or not patients experienced intubation or death.
  • Unfavourable antibody profiles, meaning low antibody titres, non-functional antibodies or both, was associated with a higher risk of intubation or death.

Want to know more click here go to source.

From -

Close

Site Language


By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close